What is abrdn Life Sciences Investors Cash Flow from Financing?
Cash from financing is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders.
For the
six
months ended in Mar. 2024,
abrdn Life Sciences Investors paid$0.00 Mil more to buy back shares than it received from issuing new shares.
It received$0.00 Mil from issuing more debt.
It paid$0.00 Mil more to buy back preferred shares than it received from issuing preferred shares.
It received$0.00 Mil from paying cash dividends to shareholders.
It received$0.00 Mil on other financial activities.
In all, abrdn Life Sciences Investorsspent$0.00 Mil on financial activities for the
six
months ended in Mar. 2024.
abrdn Life Sciences Investors Cash Flow from Financing Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Premium members only.
abrdn Life Sciences Investors Cash Flow from Financing Chart
abrdn Life Sciences Investors Cash Flow from Financing Calculation
This is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders. In the calculation of free cash flow, cash from financing is not calculated because it is not related to operating activities.
Cash Flow from Financing for the trailing twelve months (TTM) ended in Mar. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was $0.00 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
abrdn Life Sciences Investors (NYSE:HQL) Cash Flow from Financing Explanation
Cash from financing contains six items:
1. Issuance of Stock:
A company may raise cash from issuing new shares. Issuance of stock represents the cash inflow from offering common stock, which is the additional capital contribution to the entity during the period.
abrdn Life Sciences Investors's issuance of stock for the
six
months ended in Mar. 2024 was $0.00 Mil.
2. Repurchase of Stock:
A company may raise cash from issuing new shares. It can also use cash to buy back shares. Repurchase of stock represents the cash outflow to reacquire common stock during the period.
abrdn Life Sciences Investors's repurchase of stock for the
six
months ended in Mar. 2024 was $0.00 Mil.
3. Net Issuance of Debt:
Net issuance of debt is the cash a company received or spent through debt related activities such as debt issuance or debt repayment. If a company pays down its debt during the period, this number will be negative. If a company issued more debt, it receives cash and this number is positive.
abrdn Life Sciences Investors's net issuance of debt for the
six
months ended in Mar. 2024 was $0.00 Mil.
abrdn Life Sciences Investors received$0.00 Mil from issuing more debt.
4. Net Issuance of Preferred Stock:
A company may raise cash from issuing new preferred shares. It can also use cash to buy back preferred shares. If this number is positive, it means that the company has received more cash from issuing preferred shares than it has paid to buy back preferred shares. If this number is negative, it means that company has paid more cash to buy back preferred shares than it has received for issuing preferred shares.
abrdn Life Sciences Investors's net issuance of preferred for the
six
months ended in Mar. 2024 was $0.00 Mil.
abrdn Life Sciences Investors paid$0.00 Mil more to buy back preferred shares than it received from issuing preferred shares.
5. Cash Flow for Dividends:
Cash flow for dividends refers to the payment of cash to shareholders as dividends when the company generates income.
abrdn Life Sciences Investors's cash flow for dividends for the
six
months ended in Mar. 2024 was $0.00 Mil.
abrdn Life Sciences Investors received$0.00 Mil from paying cash dividends to shareholders.
6. Other Financing:
Money spent or earned by company from other financial activities.
abrdn Life Sciences Investors's other financing for the
six
months ended in Mar. 2024 was $0.00 Mil.
abrdn Life Sciences Investors received$0.00 Mil on other financial activities.
abrdn Life Sciences Investors Cash Flow from Financing Related Terms
Thank you for viewing the detailed overview of abrdn Life Sciences Investors's Cash Flow from Financing provided by GuruFocus.com. Please click on the following links to see related term pages.
abrdn Life Sciences Investors (abrdn Life Sciences Investors) Business Description
abrdn Life Sciences Investors operates as a non-diversified closed-end management investment company. Its investment objective is to seek long-term capital appreciation by investing primarily in securities of Life Sciences companies. It invests in securities of public and private companies that are believed by the Fund's Investment Adviser, abrdn Inc to have significant potential for above-average growth.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
:HQL has been successfully added to your 